Insulin lispro

From Wikipedia, the free encyclopedia

Insulin lispro
Systematic (IUPAC) name
?
Identifiers
CAS number	133107-64-9
ATC code	A10AB04
PubChem	16132438
DrugBank	BTD00065
Chemical data
Formula	C257H389N65O77S6
Mol. mass	5813.63 g/mol
Pharmacokinetic data
Bioavailability	?
Metabolism	?
Half life	?
Excretion	?
Therapeutic considerations
Pregnancy cat.	C(US)
Legal status	POM(UK) ℞-only(US)
Routes	Subcutaneous

Insulin lispro (marketed by Lilly as "Humalog") is a fast acting insulin analogue; it was the first insulin analogue.

It was engineered through recombinant DNA technology so that the penultimate lysine and proline residues on the C-terminal end of the B-chain were reversed. This modification did not alter receptor binding, but blocked the formation of insulin dimers and hexamers. This allowed larger amounts of active monomeric insulin to be available for postprandial (after meal) injections. ^[1]

It has been shown by Shimoda et al. that, when comparing three insulin delivery methods, i.v. (intravenous) regular insulin, s.c. (subcutaneous) insulin Lispro, and s.c. regular insulin, that s.c. insulin Lispro performs almost as well as i.v. regular insulin in handling meal disturbances. S.c. regular insulin performed worse than s.c. insulin lispro, resulting in postprandial glucose peaks, in addition to postprandial hypoglycemia.

[edit] References

1. ^ [http://www.aafp.org/afp/980115ap/noble.html Insulin Lispro: A Fast-Acting Insulin Analog]. Retrieved on 2007-06-08.

v • d • e Oral antidiabetic drugs and Insulin analogs (A10) Biguanides Metformin Sulfonylureas Carbutamide, Chlorpropamide, Glibenclamide (Glyburide), Gliclazide, Glimepiride, Glipizide, Gliquidone, Tolazamide, Tolbutamide Alpha-glucosidase inhibitors Acarbose, Miglitol, Voglibose Thiazolidinediones (TZD) Pioglitazone, Rivoglitazone†, Rosiglitazone, Troglitazone‡ Meglitinides Nateglinide, Repaglinide, Mitiglinide Dipeptidyl peptidase-4 (DPP-4) inhibitors Alogliptin†, Saxagliptin†, Sitagliptin, Vildagliptin Glucagon-like peptide-1 analog Exenatide, Liraglutide†, Albiglutide† Amylin analog Pramlintide Insulin analogs fast acting (Insulin lispro, Insulin aspart, Insulin glulisine), long acting (Insulin glargine, Insulin detemir), Inhalable insulin (Exubera) Dual PPAR agonists Aleglitazar†, Muraglitazar§, Tesaglitazar§ SGLT2 inhibitor Dapagliflozin†, Remogliflozin† †Undergoing clinical trials. ‡ Withdrawn from market. §Development halted.